胰岛素增敏剂防治非酒精性脂肪性肝病临床价值

被引：20

作者：

颜红梅

高鑫

机构：

[1] 复旦大学附属中山医院内分泌科

来源：

中国实用内科杂志 | 2009年 / 29卷 / 05期

关键词：

非酒精性脂肪性肝病; 胰岛素抵抗; 胰岛素增敏剂;

D O I：

暂无

中图分类号：

R575 [肝及胆疾病];

学科分类号：

100201 [内科学];

摘要：

非酒精性脂肪性肝病(NAFLD)已成为国内外常见慢性肝脏疾病之一,由于胰岛素抵抗在NAFLD发病机制中的重要作用,胰岛素增敏剂逐渐成为有前景的NAFLD治疗药物。本文分析总结了近年来胰岛素增敏剂治疗NAFLD的文献,结果提示,吡格列酮(PGZ)、罗格列酮(RGZ)和二甲双胍(MF)均能改善NAFLD患者肝酶水平和胰岛素抵抗;在改善肝脏组织学方面,PGZ有随机双盲对照研究证据的支持,显示出良好的应用前景;而MF与RGZ,缺少有力的人体研究支持。大多数研究中患者可以耐受胰岛素增敏剂,未见明显不良反应。目前已有研究的样本量均不大,疗程大多不超过2年,因此,仍需要设计良好的临床试验来进一步评价胰岛素增敏剂对NAFLD的疗效和安全性。

引用

页码：405 / 409

页数：5

共 11 条

[1]

非酒精性脂肪肝病患者中肝酶与代谢综合征的关系[J] 刘蒙;颜红梅;高鑫;高键; 中华医学杂志 2007, 04

[2]

肝脏脂肪含量与胰岛素抵抗及代谢综合征 [J].

颜红梅 ;

高鑫 ;

刘蒙 ;

顾迁 ;

张斌 ;

李湘 .

中华医学杂志, 2008, (18)

[3]

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J] A. Nar;O. Gedik Acta Diabetologica 2009,

[4]

Metformin use in children with nonalcoholic fatty liver disease: An open-label; 24-month; observational pilot study[J] Valerio Nobili;Melania Manco;Paolo Ciampalini;Anna Alisi;Rita Devito;Elisabetta Bugianesi;Matilde Marcellini;Giulio Marchesini Clinical Therapeutics 2008,

[5]

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial[J] Vlad Ratziu;Philippe Giral;Sophie Jacqueminet;Fréderic Charlotte;Agnès Hartemann–Heurtier;Lawrence Serfaty;Philippe Podevin;Jean–Marc Lacorte;Carole Bernhardt;Eric Bruckert;André Grimaldi;Thierry Poynard Gastroenterology 2008,

[6]

Liver; Muscle; and Adipose Tissue Insulin Action Is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects[J] Kevin M. Korenblat;Elisa Fabbrini;B. Selma Mohammed;Samuel Klein Gastroenterology 2008,

[7]

Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement[J] Glen Lutchman;Kittichai Promrat;David E. Kleiner;Theo Heller;Marc G. Ghany;Jack A. Yanovski;T. Jake Liang;Jay H. Hoofnagle Clinical Gastroenterology and Hepatology 2006,

[8]

The Effects of Rosiglitazone; Metformin; and Diet with Exercise in Nonalcoholic Fatty Liver Disease[J] Digestive Diseases and Sciences 2007,

[9]

Prevalence of and risk factors for fatty liver in a general population of Shanghai; China[J] Jian-Gao Fan;Jun Zhu;Xing-Jian Li;Lan Chen;Lui Li;Fei Dai;Feng Li;Shi-Yao Chen Journal of Hepatology 2005,

[10]

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone[J] Brent A. Neuschwander-Tetri;Elizabeth M. Brunt;Kent R. Wehmeier;Dana Oliver;Bruce R. Bacon Hepatology 2003,

← 1 2 →